

Woojin Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1343801/publications.pdf>

Version: 2024-02-01

96
papers

4,613
citations

147786

31
h-index

102480

66
g-index

98
all docs

98
docs citations

98
times ranked

5389
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug and Bile Acid Transporters in Rosuvastatin Hepatic Uptake: Function, Expression, and Pharmacogenetics. <i>Gastroenterology</i> , 2006, 130, 1793-1806.	1.3	542
2	The orphan nuclear receptor HNF4 α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. <i>Nature Medicine</i> , 2003, 9, 220-224.	30.7	418
3	Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 362-370.	4.7	374
4	Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2). <i>Journal of Biological Chemistry</i> , 2005, 280, 9610-9617.	3.4	316
5	Transporters and Renal Drug Elimination. <i>Annual Review of Pharmacology and Toxicology</i> , 2004, 44, 137-166.	9.4	210
6	Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 647-656.	1.5	172
7	Ethnicity-dependent Polymorphism in Na ⁺ -taurocholate Cotransporting Polypeptide (SLC10A1) Reveals a Domain Critical for Bile Acid Substrate Recognition. <i>Journal of Biological Chemistry</i> , 2004, 279, 7213-7222.	3.4	167
8	Overexpression of OATP1B3 Confers Apoptotic Resistance in Colon Cancer. <i>Cancer Research</i> , 2008, 68, 10315-10323.	0.9	122
9	Cancer Pharmacogenomics: Powerful Tools in Cancer Chemotherapy and Drug Development. <i>Oncologist</i> , 2005, 10, 104-111.	3.7	116
10	Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors. <i>Biomaterials</i> , 2018, 180, 206-224.	11.4	110
11	HEPATIC UPTAKE OF THE NOVEL ANTIFUNGAL AGENT CASPOFUNGIN. <i>Drug Metabolism and Disposition</i> , 2005, 33, 676-682.	3.3	105
12	Next-generation proteasome inhibitors for cancer therapy. <i>Translational Research</i> , 2018, 198, 1-16.	5.0	99
13	Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy. <i>AAPS Journal</i> , 2015, 17, 535-545.	4.4	91
14	Inhibitors of the Immunoproteasome: Current Status and Future Directions. <i>Current Pharmaceutical Design</i> , 2013, 19, 4140-4151.	1.9	85
15	Novel Mechanistic Insights into Ectodomain Shedding of EGFR Ligands Amphiregulin and TGF- β : Impact on Gastrointestinal Cancers Driven by Secondary Bile Acids. <i>Cancer Research</i> , 2014, 74, 2062-2072.	0.9	80
16	Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 58, 41-48.	1.5	78
17	A Cancer-Specific Variant of the <i>SLCO1B3</i> Gene Encodes a Novel Human Organic Anion Transporting Polypeptide 1B3 (OATP1B3) Localized Mainly in the Cytoplasm of Colon and Pancreatic Cancer Cells. <i>Molecular Pharmaceutics</i> , 2013, 10, 406-416.	4.6	75
18	A Common Polymorphism in the Bile Acid Receptor Farnesoid X Receptor Is Associated with Decreased Hepatic Target Gene Expression. <i>Molecular Endocrinology</i> , 2007, 21, 1769-1780.	3.7	61

#	ARTICLE	IF	CITATIONS
19	Phase 0/microdosing approaches: time for mainstream application in drug development?. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 801-818.	46.4	55
20	A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 833-838.	2.3	52
21	Sustained Delivery of Carfilzomib by Tannic Acid-Based Nanocapsules Helps Develop Antitumor Immunity. <i>Nano Letters</i> , 2019, 19, 8333-8341.	9.1	51
22	Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 3794-3802.	7.0	49
23	A Comparative In Vivo Study of Albumin-Coated Paclitaxel Nanocrystals and Abraxane. <i>Small</i> , 2018, 14, e1703670.	10.0	47
24	Proteasome Inhibitors with Pyrazole Scaffolds from Structure-Based Virtual Screening. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2036-2041.	6.4	45
25	Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib. <i>Molecular Pharmaceutics</i> , 2012, 9, 2197-2205.	4.6	41
26	Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 699-705.	2.3	41
27	Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 186-196.	2.5	41
28	Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation. <i>Journal of Controlled Release</i> , 2019, 302, 148-159.	9.9	41
29	Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome. <i>Clinical and Experimental Gastroenterology</i> , 2008, 1, 1.	2.3	36
30	Polymer Micelle Formulations of Proteasome Inhibitor Carfilzomib for Improved Metabolic Stability and Anticancer Efficacy in Human Multiple Myeloma and Lung Cancer Cell Lines. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 355, 168-173.	2.5	35
31	Lack of critical involvement of endothelial nitric oxide synthase in vascular nitrate tolerance in mice. <i>British Journal of Pharmacology</i> , 2002, 135, 299-302.	5.4	32
32	Role of hypoxia inducible factor-1 α in the regulation of the cancer-specific variant of organic anion transporting polypeptide 1B3 (OATP1B3), in colon and pancreatic cancer. <i>Biochemical Pharmacology</i> , 2013, 86, 816-823.	4.4	32
33	Emerging immunotherapy for the treatment of esophageal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 667-677.	4.1	32
34	Statistical methods for assays with limits of detection: Serum bile acid as a differentiator between patients with normal colons, adenomas, and colorectal cancer. <i>Journal of Carcinogenesis</i> , 2011, 10, 12.	2.5	29
35	Expanded Physiologically-Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 845-857.	2.5	28
36	Post-translational regulation of the major drug transporters in the families of organic anion transporters and organic anion-transporting polypeptides. <i>Journal of Biological Chemistry</i> , 2020, 295, 17349-17364.	3.4	28

#	ARTICLE	IF	CITATIONS
37	Kinetics of the Absorption, Distribution, Metabolism, and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-Activated Receptor Gamma in Rats. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 3049-3059.	3.3	27
38	Physiologically-Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter-Mediated Interactions Between Metformin and Cimetidine. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 396-406.	2.5	26
39	Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. , 1998, 19, 357-364.		25
40	Mechanism-based partial inactivation of glutathione S-transferases by nitroglycerin: tyrosine nitration vs sulfhydryl oxidation. <i>Nitric Oxide - Biology and Chemistry</i> , 2003, 8, 103-110.	2.7	25
41	Revisiting the role of the immunoproteasome in the activation of the canonical NF- κ B pathway. <i>Molecular BioSystems</i> , 2012, 8, 2295.	2.9	25
42	Enhancing Docetaxel Delivery to Multidrug-Resistant Cancer Cells with Albumin-Coated Nanocrystals. <i>Molecular Pharmaceutics</i> , 2018, 15, 871-881.	4.6	25
43	Quinic Acid-Conjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins. <i>Small</i> , 2018, 14, e1803601.	10.0	25
44	Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 1299-1311.	7.0	24
45	Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer. <i>Oncogene</i> , 2020, 39, 4567-4580.	5.9	22
46	Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx. <i>Molecular Cancer Research</i> , 2017, 15, 1096-1105.	3.4	20
47	Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4444-4455.	6.4	20
48	The Immunoproteasome: An Emerging Therapeutic Target. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 2923-2930.	2.1	19
49	Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1351-1364.	4.1	18
50	Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice. <i>PLoS ONE</i> , 2017, 12, e0173247.	2.5	18
51	Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear Pharmacokinetics. <i>Drug Metabolism and Disposition</i> , 2018, 46, 740-748.	3.3	18
52	The N-terminal region of organic anion transporting polypeptide 1B3 (OATP1B3) plays an essential role in regulating its plasma membrane trafficking. <i>Biochemical Pharmacology</i> , 2017, 131, 98-105.	4.4	17
53	Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: Application of the extended clearance concept and consideration of the effect of albumin on CYP2C metabolism and OATP1B-mediated hepatic uptake. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 125, 181-192.	4.0	17
54	Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 2073-2081.	1.9	16

#	ARTICLE	IF	CITATIONS
55	Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. <i>International Journal of Nanomedicine</i> , 2015, 10, 1201.	6.7	16
56	The Immunoproteasome as a Therapeutic Target for Hematological Malignancies. <i>Current Cancer Drug Targets</i> , 2014, 14, 537-548.	1.6	16
57	Activity-Based Near-Infrared Fluorescent Probe for LMP7: A Chemical Proteomics Tool for the Immunoproteasome in Living Cells. <i>ChemBioChem</i> , 2012, 13, 1899-1903.	2.6	15
58	Experimental and Modeling Evidence Supporting the <i>Trans</i> -Inhibition Mechanism for Preincubation Time-Dependent, Long-Lasting Inhibition of Organic Anion Transporting Polypeptide 1B1 by Cyclosporine A. <i>Drug Metabolism and Disposition</i> , 2022, 50, 541-551.	3.3	12
59	PSMB9 Codon 60 Polymorphisms Have No Impact on the Activity of the Immunoproteasome Catalytic Subunit B1i Expressed in Multiple Types of Solid Cancer. <i>PLoS ONE</i> , 2013, 8, e73732.	2.5	11
60	Comparative and quantitative assessment on statin efficacy and safety: insights into inter-statin and inter-individual variability via dose- and exposure-response relationships. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 897-911.	3.3	11
61	H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth. <i>Scientific Reports</i> , 2019, 9, 4089.	3.3	11
62	A FRET-based approach for identification of proteasome catalytic subunit composition. <i>Molecular BioSystems</i> , 2014, 10, 196-200.	2.9	10
63	Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity. <i>Therapeutic Delivery</i> , 2016, 7, 665-681.	2.2	10
64	Consideration of albumin-mediated hepatic uptake for highly protein-bound anionic drugs: Bridging the gap of hepatic uptake clearance between <i>in vitro</i> and <i>in vivo</i> . , 2022, 229, 107938.		10
65	Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 474-482.	2.5	10
66	Differential interactions of nitric oxide donors with rat oxyhemoglobin. <i>Biochemical Pharmacology</i> , 1999, 58, 671-674.	4.4	9
67	eNOS-dependent vascular interaction between nitric oxide and calcitonin gene-related peptide in mice: gender selectivity and effects on blood aggregation. <i>Regulatory Peptides</i> , 2003, 110, 115-122.	1.9	9
68	Determination of chemically reduced pyrrolbenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. <i>Journal of Mass Spectrometry</i> , 2008, 43, 42-52.	1.6	9
69	High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design. <i>ChemBioChem</i> , 2016, 17, 2115-2117.	2.6	9
70	Inhibition of Organic Anion Transporting Polypeptide 1B1 and 1B3 by Betulinic Acid: Effects of Preincubation and Albumin in the Media. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1713-1723.	3.3	9
71	Evaluation of Hepatic Uptake of OATP1B Substrates by Short Term-Cultured Plated Human Hepatocytes: Comparison With Isolated Suspended Hepatocytes. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 376-387.	3.3	8
72	Effect of Enhancers on <i>in vitro</i> and <i>in vivo</i> Skin Permeation and Deposition of S-Methyl-L-Methionine. <i>Biomolecules and Therapeutics</i> , 2017, 25, 434-440.	2.4	8

#	ARTICLE	IF	CITATIONS
73	Transient, Tunable Expression of NTCP and BSEP in MDCKII Cells for Kinetic Delineation of the Rate-Determining Process and Inhibitory Effects of Rifampicin in Hepatobiliary Transport of Taurocholate. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 365-375.	3.3	7
74	Revisiting Nonlinear Bosentan Pharmacokinetics by Physiologically Based Pharmacokinetic Modeling: Target Binding, Albeit Not a Major Contributor to Nonlinearity, Can Offer Prediction of Target Occupancy. <i>Drug Metabolism and Disposition</i> , 2021, 49, 298-304.	3.3	7
75	Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10934-10950.	6.4	7
76	Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers. <i>PLoS ONE</i> , 2014, 9, e107424.	2.5	6
77	Alternative Splicing: Expanding Diversity in Major ABC and SLC Drug Transporters. <i>AAPS Journal</i> , 2017, 19, 1643-1655.	4.4	6
78	Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 146, 341-346.	2.8	6
79	Runx3 inhibits endothelial progenitor cell differentiation and function via suppression of HIF-1 α activity. <i>International Journal of Oncology</i> , 2019, 54, 1327-1336.	3.3	6
80	Improved Prediction of the Drug-Drug Interactions of Pemaflibrate Caused by Cyclosporine A and Rifampicin via PBPK Modeling: Consideration of the Albumin-Mediated Hepatic Uptake of Pemaflibrate and Inhibition Constants With Preincubation Against OATP1B. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 517-528.	3.3	6
81	Metabolic changes of acetaminophen after intravenous administration to rats pretreated with 2-(allylthio)pyrazine. <i>Journal of Pharmaceutical Sciences</i> , 1998, 19, 273-277.		5
82	The identification of lobeclitazone metabolites in rat liver microsomes and the kinetics of the in vivo formation of the major metabolite M1 in rats. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 115, 375-382.	2.8	5
83	Targeted Degradation of Proteins by PROTACs. <i>Current Protocols in Chemical Biology</i> , 2010, 2, 71-87.	1.7	4
84	A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 419-426.	2.3	4
85	Elucidating the Catalytic Subunit Composition of Distinct Proteasome Subtypes: A Crosslinking Approach Employing Bifunctional Activity-Based Probes. <i>ChemBioChem</i> , 2015, 16, 284-292.	2.6	4
86	Suppression of Canine ATP Binding Cassette ABCB1 in Madin-Darby Canine Kidney Type II Cells Unmasks Human ABCG2-Mediated Efflux of Olaparib. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 368, 79-87.	2.5	4
87	Cell-to-Medium Concentration Ratio Overshoot in the Uptake of Statins by Human Hepatocytes in Suspension, but Not in Monolayer: Kinetic Analysis Suggesting a Partial Loss of Functional OATP1Bs. <i>AAPS Journal</i> , 2020, 22, 133.	4.4	4
88	Feasibility of the functional expression of the human organic anion transporting polypeptide 1B1 (OATP1B1) and its genetic variant 521T/C in the mouse liver. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 96, 28-36.	4.0	3
89	Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 1615-1622.	3.3	3
90	Pharmacokinetic aspects of the clinically used proteasome inhibitor drugs and efforts toward nanoparticulate delivery systems. <i>Journal of Pharmaceutical Investigation</i> , 2021, 51, 483.	5.3	3

#	ARTICLE	IF	CITATIONS
91	COMPARISON OF PHARMACOKINETICS OF M1, M2, M3, AND M4 AFTER INTRAVENOUS ADMINISTRATION OF DA-125 OR ME2303 TO MICE AND RATS. NEW ADRIAMYCIN ANALOGUES CONTAINING FLUORINE. , 1996, 17, 373-420.		2
92	Gender differences in the hepatic elimination and pharmacokinetics of lobeglitazone in rats. Biopharmaceutics and Drug Disposition, 2015, 36, 410-415.	1.9	2
93	Nanoformulations of Carfilzomib for Improved Metabolic Stability and Anti-Cancer Efficacy. FASEB Journal, 2015, 29, 620.1.	0.5	2
94	A Simple Decision Tree Suited for Identification of Early Oral Drug Candidates With Likely Pharmacokinetic Nonlinearity by Intestinal CYP3A Saturation. Journal of Pharmaceutical Sciences, 2021, 110, 510-516.	3.3	0
95	CNS-penetrant LMP2 Inhibitors as Potential Therapies for Age-related Macular Degeneration. SSRN Electronic Journal, 0, , .	0.4	0
96	Development of Epoxyketone-based Immunoproteasome-selective Inhibitors with Enhanced Brain Distribution In Vivo. FASEB Journal, 2019, 33, 670.19.	0.5	0